Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On November 6, 2025, MetaVia Inc. (MTVA) announced financial results for the third quarter of 2025 and provided a business update.</li><li>We anticipate data from the 48 mg cohort from the Phase 1 trial of DA-1726, a dual GLP1/GCGR agonist, before the end of 2025.</li><li>This cohort was added to evaluate the non-titrated maximum tolerated dose of DA-1726.</li></ul>

On November 6, 2025, MetaVia Inc. (MTVA) announced financial results for the third quarter of 2025 and provided a business update.We anticipate data from the 48 mg cohort from the Phase 1 trial of DA-1726, a dual GLP1/GCGR agonist, before the end of 2025.This cohort was added to evaluate the non-titrated maximum tolerated dose of DA-1726.

MTVA: 8-Week Data for 48 mg Cohort in Phase 1 Obesity Study Expected Before End of 2025 